Polycystic Ovary Syndrome - Improving Outcomes

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
Polycystic ovary syndrome affects a striking 9-18% of Australian reproductive aged women and has been associated with a number of metabolic abnormalities. Given the strong correlation between metabolic abnormalities and increased sympathetic activity, we hypothesise that reducing this activity using medication (moxonidine) can help improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary syndrome.
Epistemonikos ID: 9b31253088fe836cc0cc0f446bc5ffc9064b06e6
First added on: May 10, 2024